Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Down 5.59%
As of Tuesday, October 27, Caribou Biosciences, Inc.’s CRBU share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Cynthia McLaughlin
Jenna Brashear
Michael Rose
Tudor Pop
| Share Statistics | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $30.7 | $203.5 | 14% |
|
| Shares Out (Mil) | 107.5 | 55.2 | 63% |
|
| Institutional Ownership | 93.1% | 93.3% | 62% |
|
| Float (Mil) | 103.7 | 40.4 | 61% |
|
| Beta | 2.49 | 1.05 | 96% |
|
| Avg Daily Volume (000s) | 2,428 | 569 | 84% |
|
| Price Change (52-week) |
(84.4%) | 38.8% | 8% |
|
| Growth | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.0%) | 13.6% | 13% |
|
| Net Income (5yr) | (34.0%) | (10.7%) | 12% |
|
| EPS (5yr) | 16.9% | 15.4% | 62 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 57.7% | (15.7%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 3 | |
| Current EPS | ($0.278) | ($1.035) | ($0.647) | |
| Month Ago EPS | ($0.278) | ($1.035) | ($0.897) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.363) | ($1.175) | ($1.263) | |
| Year/Year Chg | 12.6% | (34.7%) | 5.9% | |
| Financials | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9 | $40 | 8% |
|
| Net Income (TTM) (Mil) | ($103) | ($44) | 11% |
|
| EPS (TTM) | ($1.027) | ($1.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($93) | ($35) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $-0 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $25 | $4 | 34% |
|
| Enterprise Value (Q1) (Mil) | ($23) | $142 | 2% |
|
| Valuation | CRBU | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.40 | 1.96 | 10% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (797.0%) | 67.6% | 0% |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (64.4%) | (47.0%) | 9% |
|
| ROE | (93.8%) | (51.8%) | 9% |
|
| Liabilities to Assets | 37.7% | 29.6% | 28% |
|
| F-Score | 3 | 3 | 18% |
|
Caribou Biosciences, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors